
    
      Consecutively enrolled eligible women will be randomized into one of two different treatment
      groups: 1) Group receiving BTX-A, and 2) Group receiving a placebo. All consenting subjects
      will be randomized to receive either a single injection of 100 units of BTX-A, or a placebo
      (saline water), during surgery in the pectoralis major muscle on the operated side once the
      mastectomy and the breast reconstruction have been completed. Expected duration of subject
      participation is 4 months.
    
  